18:53 , Feb 7, 2019 |  BC Week In Review  |  Company News

Gilead reports $820M impairment on Kite anti-BCMA therapy

As Daniel O’Day prepares to step in as the company’s chairman and CEO, Gilead Sciences Inc. (NASDAQ:GILD) reported 4Q18 earnings that included an $820 million impairment charge for anti-BCMA therapy KITE-585, one of the compounds...
01:05 , Feb 5, 2019 |  BC Extra  |  Company News

Gilead reports $820M impairment on Kite anti-BCMA therapy

As Daniel O’Day prepares to step in as the company’s chairman and CEO, Gilead Sciences Inc. (NASDAQ:GILD) reported 4Q18 earnings that included an $820 million impairment charge for anti-BCMA therapy KITE-585, one of the compounds...
21:36 , Jan 26, 2019 |  BioCentury  |  Product Development

Raising the BD bar

Innovator biotechs say that the business development bar has been raised for companies developing new modalities, with potential partners seeking proof of mechanism on top of proof of efficacy. A host of products based on...
20:20 , Dec 21, 2018 |  BC Week In Review  |  Company News

Merck KGaA puts CAR T development in Intrexon's hands

Merck KGaA (Xetra:MRK) has become the latest pharma to realize early stage CAR T technologies may be best in the hands of smaller companies after transferring to Intrexon Corp. (NYSE:XON) development rights for partnered CAR...
19:25 , Dec 21, 2018 |  BC Week In Review  |  Company News

Gilead expands immuno-oncology pipeline with license from Agenus

Gilead Sciences Inc. (NASDAQ:GILD) received rights to a bispecific immuno-oncology molecule and options for two additional immuno-oncology candidates from Agenus Inc. (NASDAQ:AGEN). Gilead received exclusive, worldwide rights to AGEN1423, options to bispecific antibody AGEN1223 and...
00:06 , Dec 21, 2018 |  BC Extra  |  Company News

Gilead expands immuno-oncology pipeline with license from Agenus

Gilead Sciences Inc. (NASDAQ:GILD) received rights to a bispecific immuno-oncology molecule and options for two additional immuno-oncology candidates from Agenus Inc. (NASDAQ:AGEN). The deal, Gilead's second of the week, will also extend Agenus’ cash reserves....
22:54 , Dec 20, 2018 |  BC Extra  |  Company News

Merck KGaA puts CAR T development in Intrexon's hands

Merck KGaA (Xetra:MRK) has become the latest pharma to realize early stage CAR T technologies may be best in the hands of smaller companies after transferring to Intrexon Corp. (NYSE:XON) development rights for partnered CAR...
04:43 , Dec 15, 2018 |  BioCentury  |  Product Development

O’Day’s expansive task at Gilead

A fresh executive team and a track record of building deep portfolios could allow incoming Gilead Sciences Inc. chairman and CEO Daniel O’Day to do what his predecessors couldn’t: make Gilead a leader outside of...
21:17 , Dec 14, 2018 |  BC Week In Review  |  Company News

Veteran Roche cancer executive O'Day to lead Gilead

Daniel O’Day will inherit a pile of cash and a company that is looking beyond infectious disease to carve out its space in cancer and build on its newly acquired CAR T platform when he...
20:23 , Dec 10, 2018 |  BC Extra  |  Company News

Veteran Roche cancer executive O'Day to lead Gilead

Daniel O’Day will inherit a pile of cash and a company that is looking beyond infectious disease to carve out its space in cancer and build on its newly acquired CAR T platform when he...